Biotech: Page
-
New data could widen use of AstraZeneca, Amgen immune disease drug
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
By Delilah Alvarado • Aug. 27, 2026 -
Retrieved from Revolution Medicines.
Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say
Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.
By Kristin Jensen • Aug. 27, 2026 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrative drug launch.
By Gwendolyn Wu • Updated Aug. 27, 2026 -
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.
By Kristin Jensen • Aug. 26, 2026 -
News roundup
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
By BioPharma Dive staff • Aug. 26, 2026 -
New Jazz cancer drug approval could drive blockbuster sales
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
By Jonathan Gardner • Aug. 25, 2026 -
Emerging biotech
Will a ‘reset’ reignite investment in women’s health startups?
After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI and a widening definition of what constitutes women’s health could spur a rebound, some say.
By Delilah Alvarado • Aug. 25, 2026 -
Emerging biotech
Young startups miss out on biotech venture funding rebound, MassBio says
A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”
By Gwendolyn Wu • Aug. 25, 2026 -
News roundup
FDA extends review of Capricor cell therapy; Pain drug startup to go public
The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.
By Ben Fidler • Aug. 24, 2026 -
Emerging biotech
Cellares, a cell therapy manufacturing specialist, to lay off 100 employees
The restructuring comes after an unnamed "large pharmaceutical customer" terminated a contract with the company, Cellares CEO Fabian Gerlinghaus posted on LinkedIn.
By Gwendolyn Wu • Aug. 24, 2026 -
Obesity drugs
Roche commits to lean-mass preservation with Hanmi obesity deal
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
By Jonathan Gardner • Aug. 24, 2026 -
Sponsored by PharmaForceIQ
Pharma marketers need a share-of-answer strategy before AI spend
AI is changing how HCPs seek answers. Pharma marketers need a new strategy.
Aug. 24, 2026 -
News roundup
Shareholder pressures Capricor; Lilly dives deeper into vaccines
Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.
By BioPharma Dive staff • Aug. 21, 2026 -
Vaccines
Cancer vaccine win restores Wall Street’s faith in Moderna
Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet.
By Delilah Alvarado , Ben Fidler • Aug. 20, 2026 -
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna shares.
By Jonathan Gardner • Aug. 19, 2026 -
News roundup
AstraZeneca scores in lung cancer; Sandoz inks a China deal
A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.
By BioPharma Dive staff • Aug. 18, 2026 -
Amylyx’s bet on a GLP-1 blocker pays off
A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.
By Jacob Bell • Aug. 18, 2026 -
Vaccines
FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax
Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
By Alexandra Pecci • Aug. 17, 2026 -
News roundup
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.
By BioPharma Dive staff • Aug. 14, 2026 -
Biotech initiatives pick up as more regions race to become hubs
New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.
By Alexandra Pecci • Aug. 14, 2026 -
New Taiho, Cullinan data heats up lung cancer drug battle
The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
By Jonathan Gardner • Aug. 13, 2026 -
Profile
Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’
Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
By Alexandra Pecci • Aug. 12, 2026 -
Brain drug revival
Psychedelics developer Definium scores more positive data for LSD pill
Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.
By Jacob Bell • Aug. 12, 2026 -
News roundup
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.
By BioPharma Dive staff • Aug. 12, 2026 -
Immune reset
Boulevard starts up with $65M to pursue targeted autoimmune drugs
Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.
By Gwendolyn Wu • Aug. 12, 2026